| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| 10mg | |||
| Other Sizes |
| Targets |
5alpha-THDOC targets GABAA receptors as a positive modulator. GABAA receptors are ligand-gated ion channels that mediate inhibitory neurotransmission in the central nervous system. By enhancing neuronal responses to low concentrations of α4β1δ GABAA receptors, 5alpha-THDOC potentiates GABA-mediated inhibition. This neurosteroid modulation of GABAA receptors is involved in the regulation of anxiety, seizure susceptibility, and cognitive function.
|
|---|---|
| ln Vitro |
In vitro, 5alpha-THDOC enhances neuronal responses to low concentrations of α4β1δ GABAA receptors. As a positive modulator of GABAA receptors, it potentiates the effects of GABA, the primary inhibitory neurotransmitter in the brain. Its activity has been characterized in electrophysiological studies using recombinant GABAA receptors expressed in Xenopus oocytes or mammalian cells. The compound's potency and efficacy as a GABAA modulator have been established.
|
| ln Vivo |
In vivo, 5alpha-THDOC is an endogenous neurosteroid that modulates GABAA receptor function. It is used in the study of neurological disorders such as Alzheimer's disease. Neurosteroids like 5alpha-THDOC have been shown to have anticonvulsant, anxiolytic, and sedative effects. They also play a role in neuroprotection and cognitive function. The compound's in vivo effects are mediated through its positive modulation of GABAA receptors.
|
| Enzyme Assay |
In non-cell-based receptor binding assays, 5alpha-THDOC's affinity for GABAA receptors is evaluated using radioligand competition binding experiments. Membrane preparations from brain tissue or cells expressing recombinant GABAA receptors are incubated with a radiolabeled GABAA receptor ligand (such as [³H]muscimol or [³H]flunitrazepam) and varying concentrations of 5alpha-THDOC. After incubation, bound and free radioligand are separated by filtration, and radioactivity is measured. Competition curves are generated to determine IC50 and Ki values.
|
| Cell Assay |
In vitro cellular assays for 5alpha-THDOC involve measuring its effects on GABAA receptor-mediated currents in cultured cells. Cells expressing recombinant GABAA receptors (such as α4β1δ subunits) are treated with 5alpha-THDOC in the presence of GABA, and receptor activation is assessed using patch-clamp electrophysiology or fluorescence-based membrane potential assays. The compound's ability to potentiate GABA-evoked currents is quantified to determine its positive modulatory activity.
|
| Animal Protocol |
In vivo animal studies for 5alpha-THDOC have been conducted in models of neurological disorders. The compound is typically administered via intraperitoneal or oral routes, and its effects on behavior, seizure susceptibility, anxiety, and cognitive function are assessed. Studies have investigated its role in Alzheimer's disease models. However, specific protocols and detailed data are limited in publicly available sources.
|
| ADME/Pharmacokinetics |
5alpha-THDOC has a molecular weight of 334.49 and a molecular formula of C21H34O3. As an endogenous neurosteroid, it is synthesized in the brain and periphery. It is metabolized by steroid-metabolizing enzymes. The compound is lipophilic and can cross the blood-brain barrier. Detailed pharmacokinetic parameters are available from neurosteroid research literature.
|
| Toxicity/Toxicokinetics |
As an endogenous neurosteroid and research compound, 5alpha-THDOC is not intended for human use as a therapeutic agent. Comprehensive toxicology studies have not been extensively published, but the compound is generally considered safe for laboratory use. It should be handled with appropriate safety precautions. Its safety profile is consistent with that of other neurosteroids used in research.
|
| Additional Infomation |
5α-THDOC is a 21-hydroxysteroid.
5alpha-THDOC (3α,21-Dihydroxy-5α-pregnan-20-one, Tetrahydrodeoxycorticosterone) is an endogenous neurosteroid and a positive modulator of GABAA receptors. It enhances neuronal responses to low concentrations of α4β1δ GABAA receptors. It is used in the study of neurological disorders such as Alzheimer's disease. 5alpha-THDOC is a research compound and is not an approved drug. |
| Molecular Formula |
C21H34O3
|
|---|---|
| Molecular Weight |
334.49286
|
| Exact Mass |
334.251
|
| CAS # |
567-02-2
|
| PubChem CID |
101771
|
| Appearance |
White to off-white solid powder
|
| Density |
1.115g/cm3
|
| Boiling Point |
470.3ºC at 760mmHg
|
| Flash Point |
252.3ºC
|
| Index of Refraction |
1.54
|
| LogP |
3.567
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
24
|
| Complexity |
517
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C[C@]12CC[C@H](C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4C(=O)CO)C)O
|
| InChi Key |
CYKYBWRSLLXBOW-GDYGHMJCSA-N
|
| InChi Code |
InChI=1S/C21H34O3/c1-20-9-7-14(23)11-13(20)3-4-15-16-5-6-18(19(24)12-22)21(16,2)10-8-17(15)20/h13-18,22-23H,3-12H2,1-2H3/t13-,14+,15-,16-,17-,18+,20-,21-/m0/s1
|
| Chemical Name |
2-hydroxy-1-[(3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~298.96 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9896 mL | 14.9481 mL | 29.8963 mL | |
| 5 mM | 0.5979 mL | 2.9896 mL | 5.9793 mL | |
| 10 mM | 0.2990 mL | 1.4948 mL | 2.9896 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
